A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Immune globulin (Primary)
- Indications Postpoliomyelitis syndrome
- Focus Therapeutic Use
- Acronyms FORCE
- Sponsors Grifols
Most Recent Events
- 13 Mar 2025 Primary endpoint (Change from baseline in 2MWD) has been met, as per Grifols Media release.
- 13 Mar 2025 Results published in the Grifols Media Release
- 30 Jun 2024 This trial has been discontinued in Romania, according to European Clinical Trials Database record.